Skip to content
Clinical Trials – home

St. Olavs Hospital HF

Verified siteinfo

Norway Prinsesse Kristinas Gate 3, 7030 Trondheim, Norway

  • 102 trials recruiting
  • Acute myeloid leukaemia · Plasma cell myeloma · Non-small cell lung cancer
  • Adults and children

About Specializations

St. Olavs Hospital HF in Trondheim, Norway specialises in clinical trials of conditions such as Acute myeloid leukaemia, Plasma cell myeloma, Non-small cell lung cancer, Chronic lymphocytic leukaemia, and other specialisations. This site conducts important research.

Main research areas of the site

Hematologic Malignancies and Blood Disorders

At St. Olavs Hospital HF in Trondheim, the Dept. Of Hematology is strongly focused on hematologic diseases and blood cancers. Research includes major efforts in acute leukemias, lymphomas, multiple myeloma, and immune-mediated blood disorders, with trials aimed at improving survival, deepening treatment responses, and reducing relapse.

  • Studies in acute lymphoblastic leukemia and acute myeloid leukemia are testing better treatment strategies for children, adolescents, and adults.
  • Lymphoma research covers mantle cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, and related subtypes.
  • Multiple myeloma trials are evaluating ways to improve response depth, maintenance outcomes, and disease control.
  • Other work addresses immune thrombocytopenia, cold agglutinin disease, and autoimmune cytopenias.

The overall goal is to refine treatment effectiveness and support more durable remission across a wide range of hematology conditions.

Oncology and Solid Tumor Research

The site also supports broad cancer research across several major solid tumors. Trials explore new treatment options for breast cancer, lung cancer, colorectal cancer, prostate cancer, pancreatic cancer, and gynecologic cancers, with a focus on improving survival and disease control.

  • Breast cancer studies include approaches for HER2-positive and high-risk disease.
  • Lung cancer research spans both non-small cell and small-cell lung cancer in advanced settings.
  • Colorectal cancer and pancreatic cancer trials are evaluating more effective treatment combinations.
  • Prostate cancer research focuses on advanced and treatment-resistant disease.

These studies are designed to test new therapies, compare treatment strategies, and improve outcomes for patients with difficult-to-treat malignancies.

Neuro-Oncology and Nervous System Diseases

Clinical research at the site includes important work in nervous system diseases and brain tumors. Trials are studying conditions such as glioblastoma, glioma, medulloblastoma, ependymoma, and other rare central nervous system tumors, with the aim of improving tumor control and patient outcomes.

  • Glioma and glioblastoma studies are assessing new treatment approaches for recurrent and newly diagnosed disease.
  • Medulloblastoma research focuses on high-risk and recurrent pediatric cases.
  • Ependymoma and other rare brain tumor trials address limited-treatment situations.
  • Additional work includes studies in multiple sclerosis and other neurological disorders.

This research aims to advance both neuro-oncology and broader neurology care through better therapies and improved disease management.

Immunology, Rheumatology, and Autoimmune Conditions

The research portfolio includes several immune system and autoimmune diseases. Trials are examining rheumatoid arthritis, juvenile idiopathic arthritis, Crohn's disease, ulcerative colitis, and multiple sclerosis, alongside other inflammatory and immune-mediated conditions.

  • Rheumatoid arthritis studies are looking at better long-term disease control.
  • Juvenile idiopathic arthritis research aims to improve sustained inactive disease.
  • Inflammatory bowel disease trials include Crohn's disease and ulcerative colitis.
  • Multiple sclerosis studies are evaluating ways to slow progression and improve outcomes.

These trials focus on testing more effective and better-tolerated treatments for chronic autoimmune disorders.

Cardiovascular, Metabolic, and Endocrine Research

At this hospital site, research also covers cardiovascular disease, metabolic disorders, and endocrine conditions. Trials include studies in heart failure, Takotsubo syndrome, hypertrophic cardiomyopathy, type 1 diabetes, type 2 diabetes, and obesity, with a strong emphasis on improving everyday clinical care.

  • Heart disease studies examine outcomes in coronary, cardiomyopathic, and heart failure conditions.
  • Diabetes research addresses both type 1 diabetes and type 2 diabetes.
  • Obesity and related metabolic problems are being studied in patients with complex comorbidities.
  • Endocrine trials also include conditions such as thyroid eye disease and adrenal disorders.

The purpose of this work is to improve symptom control, reduce complications, and identify more effective long-term treatment options.

Respiratory, Headache, and Other Specialized Clinical Studies

The site’s trial activity extends into several additional therapeutic areas, including respiratory diseases, headache disorders, ear and eye conditions, and selected pregnancy-related and surgical topics. Research here often focuses on practical questions that can directly improve patient care.

  • Chronic obstructive pulmonary disease and other lung diseases are being studied to improve respiratory outcomes.
  • Migraine and cluster headache trials aim to reduce pain and treatment burden.
  • Hearing loss, eye disease, and pregnancy complications are also represented in the research portfolio.
  • Some studies evaluate supportive care, symptom relief, and better recovery after procedures.

These projects broaden the site’s research profile beyond oncology and hematology, reflecting a wide-ranging commitment to clinical research across multiple specialties.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Prinsesse Kristinas Gate 37030 TrondheimNorway
Recruiting now
102 trials
Conditions studied
137
Partner status
Verified site

More sites in TrondheimNorway

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

180 clinical trials

Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Golimumab
  • Sponsor:Janssen Cilag International

Randomized Phase III trial of elecoglipron plus dapagliflozin on kidney outcomes and mortality in adults with chronic kidney disease

Registered drug
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004
  • Sponsor:AstraZeneca AB

Study of lunsekimig versus placebo in adults with inadequately controlled eosinophilic COPD

Investigational
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Lunsekimig
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Cachexia

Recruiting

A Study of Visugromab Compared to Placebo in Patients with Cancer-Related Cachexia to Test How Well It Works and How Safe It Is

Investigational
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Visugromab
  • Sponsor:CatalYm GmbH

Study of vicadrostat and empagliflozin combination in patients with type 2 diabetes, high blood pressure and cardiovascular disease

Registered drug
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:BI 690517
  • Sponsor:Boehringer Ingelheim Espana S.A.

Study on the Effects of Budesonide, Glycopyrronium, and Formoterol Fumarate for Patients with Chronic Obstructive Pulmonary Disease (COPD)

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Budesonide
  • Sponsor:AstraZeneca AB

Study of LY3537982, pembrolizumab, and a drug combination for patients with advanced non-small cell lung cancer and a KRAS G12C mutation

Registered drug
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Eli Lilly & Co.

A Study of Baricitinib to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes

Registered drug
Countries:NorwayNorway
  • Participants:0–17 years · 18–64 years
  • Substances:Baricitinib
  • Sponsor:Eli Lilly & Co.

Efficacy and Safety of JNJ-78934804 (guselkumab and golimumab) in Adults with Moderately to Severely Active Ulcerative Colitis

InvestigationalNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Golimumab
  • Sponsor:Janssen Cilag International

Ticagrelor, Acetylsalicylic Acid and Prasugrel in Patients with Acute Coronary Syndrome: A Study of Antiplatelet Management

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Instituto De Investigacion Sanitaria Fundacion Jimenez Diaz

Comparing Daraxonrasib Alone or Combined with Gemcitabine and Paclitaxel Albumin‑Bound vs Standard Chemotherapy in Patients with Metastatic Pancreatic Adenocarcinoma

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Gemcitabine
  • Sponsor:Revolution Medicines Inc.

Randomized Study of INCB161734 Plus Standard Chemotherapy Drug Combination in Untreated KRAS G12D Metastatic Pancreatic Ductal Adenocarcinoma Patients

Registered drug
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Incyte Corp.
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.